Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • Drusas@kbin.social
    link
    fedilink
    arrow-up
    15
    ·
    1 year ago

    As a high-risk individual, this fucking sucks. Capitalist vultures trying to bankrupt me everywhere I turn.

    • Franzia@lemmy.blahaj.zone
      link
      fedilink
      arrow-up
      3
      arrow-down
      1
      ·
      1 year ago

      Oh dear I read this wrong at first, thinking you were flexing that you take risks. I’m thinking “well my life is boring and this sucks for me too?” 🤣